Altimmune, Inc. Common Stock
Veridion Score
Composite trend over time
Why is ALT moving today?
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ALT.
ALT insider activity
Altimmune, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for ALT.
ALT contract awards, year to date.
Public federal awards linked to this ticker.
ALT lobbying filings, year to date.
Registered lobbying filings matched to Altimmune, Inc. Common Stock.